Analysts Set REGENXBIO Inc. (NASDAQ:RGNX) Price Target at $35.64

Shares of REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the twelve ratings firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $35.64.

Several research firms have commented on RGNX. StockNews.com upgraded shares of REGENXBIO from a "sell" rating to a "hold" rating in a report on Friday, September 20th. Chardan Capital reissued a "buy" rating and issued a $52.00 price target on shares of REGENXBIO in a research note on Tuesday, October 22nd. Morgan Stanley restated an "overweight" rating and set a $22.00 price target on shares of REGENXBIO in a research report on Friday. Raymond James reiterated an "outperform" rating and issued a $18.00 price objective on shares of REGENXBIO in a report on Thursday, October 10th. Finally, Barclays dropped their target price on REGENXBIO from $55.00 to $50.00 and set an "overweight" rating for the company in a report on Monday, August 5th.

Insider Buying and Selling

In other REGENXBIO news, Director Argeris N. Karabelas sold 10,000 shares of REGENXBIO stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $10.11, for a total transaction of $101,100.00. Following the completion of the transaction, the director now owns 11,286 shares in the company, valued at approximately $114,101.46. The trade was a 46.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 13.13% of the stock is currently owned by insiders.

Hedge Funds Weigh In On REGENXBIO

Several institutional investors and hedge funds have recently modified their holdings of RGNX. Redmile Group LLC increased its stake in REGENXBIO by 7.1% during the 3rd quarter. Redmile Group LLC now owns 4,892,902 shares of the biotechnology company's stock valued at $51,327,000 after purchasing an additional 323,100 shares in the last quarter. Vanguard Group Inc. increased its position in shares of REGENXBIO by 9.8% during the first quarter. Vanguard Group Inc. now owns 4,876,881 shares of the biotechnology company's stock valued at $102,756,000 after acquiring an additional 436,043 shares in the last quarter. Geode Capital Management LLC raised its holdings in REGENXBIO by 4.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,088,651 shares of the biotechnology company's stock worth $11,422,000 after acquiring an additional 44,037 shares during the last quarter. Integral Health Asset Management LLC lifted its position in REGENXBIO by 25.0% in the 2nd quarter. Integral Health Asset Management LLC now owns 950,000 shares of the biotechnology company's stock valued at $11,115,000 after acquiring an additional 190,000 shares in the last quarter. Finally, Assenagon Asset Management S.A. boosted its stake in REGENXBIO by 258.7% during the 2nd quarter. Assenagon Asset Management S.A. now owns 816,384 shares of the biotechnology company's stock valued at $9,552,000 after purchasing an additional 588,773 shares during the last quarter. 88.08% of the stock is currently owned by institutional investors.

REGENXBIO Trading Down 13.6 %

Shares of NASDAQ:RGNX opened at $9.63 on Friday. REGENXBIO has a 52-week low of $8.53 and a 52-week high of $28.80. The firm has a fifty day moving average of $10.50 and a 200 day moving average of $12.28.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.